Review article · 2026 · Open access

Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs

Mark Gibson, Victoria Allen, Maryam A. Adas, Iman Muzafar, Samaad Muzafar, Nithya Suresh, Youngsung Yoon, Leigh De Gracia, Rohan Chavali, Hassan Hussain, Amanda Mootoo, Jeremy Philip Brown and 6 more

Annals of the Rheumatic Diseases · Published 1 July 2026 · DOI 10.1016/j.ard.2026.06.017

Open PDFView at the publisherCite this paper

In brief

“Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs” is a 2026 review article by Mark Gibson and 17 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 4 citations as of 19 November 2026, which puts it in the top 3% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
4
Most cited in
2026 (4)
Field-weighted impact
3.44
References
51
Authors
18

Abstract

OBJECTIVES: The Oral Rheumatoid Arthritis Trial Surveillance trial identified increased malignancy risk with tofacitinib vs tumour necrosis factor inhibitors (TNFis) in rheumatoid arthritis (RA), leading to class-wide regulatory warnings for Janus kinase inhibitors (JAKis). Comparative cancer risk vs other advanced therapies and across immune-mediated inflammatory diseases (IMIDs) remains uncertain. The objective was to estimate relative and absolute cancer risk associated with JAKi vs other advanced therapies across IMIDs. METHODS: MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026 for phases II to IV randomised trials and long-term extension studies of licensed advanced therapies in adults with RA, psoriasis (PsO)/psoriatic arthritis (PsA), or inflammatory bowel disease (IBD) reporting malignancy outcomes. Bayesian class-level network meta-analyses using Poisson models estimated incidence rate ratios (RRs) vs standard care (placebo or methotrexate monotherapy). It includes all malignancies including nonmelanoma skin cancer. RESULTS: A total of 305 studies (164,824 participants; 264,100 person-years exposure) were included, comprising 174 studies across IMIDs, 123 in RA, 129 in PsO/PsA, and 54 in IBD. In the combined IMID network, JAKi were associated with higher malignancy risk than TNFi (RR: 1.60; 95% credible interval [CrI]: 1.27-2.02) and standard care (RR: 1.85; 95% CrI: 1.38-2.47). Similar directional findings were observed across RA, PsO/PsA, and IBD networks. Interleukin-6 (IL-6), Interleukin-17 (IL-17), Interleukin-23 (IL-23), Interleukin-12/23 (IL-12/23), Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), B-lymphocyte antigen CD20 (CD20)-targeting therapies showed risks broadly comparable with TNFi. Absolute excess cancer risk with JAKi compared with TNFi was negligible in standard-risk populations (+0.037 cancers per 1000 person-years exposure [PYE]; ∼1 additional cancer per 27,000 PYE) but meaningful in higher-risk populations (+6.814 cancers per 1000 PYE; ∼1 additional cancer per 147 PYE). CONCLUSIONS: Across IMIDs, JAKi were consistently associated with higher malignancy risk relative to TNFi and standard care, extending regulatory warnings beyond RA and emphasising the need for risk-stratified treatment decisions.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Gibson, M., Allen, V., Adas, M. A., Muzafar, I., Muzafar, S., Suresh, N., Yoon, Y., De Gracia, L., Chavali, R., Hussain, H., Mootoo, A., Brown, J. P., Bechman, K., Russell, M., Norton, S., Phillippo, D., Welton, N. J., & Galloway, J. B. (2026). Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.06.017

MLA 9

Gibson, Mark, et al. “Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs.” Annals of the Rheumatic Diseases, 2026. https://doi.org/10.1016/j.ard.2026.06.017.

Chicago

Gibson, Mark, Victoria Allen, Maryam A. Adas, Iman Muzafar, Samaad Muzafar, Nithya Suresh, Youngsung Yoon, et al. 2026. “Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs.” Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.06.017.

Harvard

Gibson, M. et al. (2026) ‘Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs’, Annals of the Rheumatic Diseases. doi:10.1016/j.ard.2026.06.017.

IEEE

M. Gibson et al., “Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs,” Annals of the Rheumatic Diseases, 2026, doi: 10.1016/j.ard.2026.06.017.

BibTeX

@article{gibson2026cancer,
  title     = {{Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs}},
  author    = {Gibson, Mark and Allen, Victoria and Adas, Maryam A. and Muzafar, Iman and Muzafar, Samaad and Suresh, Nithya and Yoon, Youngsung and De Gracia, Leigh and Chavali, Rohan and Hussain, Hassan and Mootoo, Amanda and Brown, Jeremy Philip and Bechman, Katie and Russell, Mark and Norton, Sam and Phillippo, David and Welton, Nicky J. and Galloway, James Benjamin},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2026},
  doi       = {10.1016/j.ard.2026.06.017},
  url       = {https://doi.org/10.1016/j.ard.2026.06.017}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • JAK inhibitors
  • cancer risk
  • immune-mediated inflammatory diseases
  • rheumatoid arthritis
  • psoriasis
  • psoriatic arthritis
  • inflammatory bowel disease
  • tumor necrosis factor inhibitors

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Gibson, M., Allen, V., Adas, M. A., Muzafar, I., Muzafar, S., Suresh, N., Yoon, Y., De Gracia, L., Chavali, R., Hussain, H., Mootoo, A., Brown, J. P., Bechman, K., Russell, M., Norton, S., Phillippo, D., Welton, N. J., & Galloway, J. B. (2026). Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.06.017

How many times has this paper been cited?

4 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the PDF from this page.

Who wrote this paper?

Mark Gibson, Victoria Allen, Maryam A. Adas, Iman Muzafar, Samaad Muzafar, Nithya Suresh, Youngsung Yoon, Leigh De Gracia, Rohan Chavali, Hassan Hussain, Amanda Mootoo, Jeremy Philip Brown and 6 more.

What is the DOI of this paper?

10.1016/j.ard.2026.06.017, permanently at https://doi.org/10.1016/j.ard.2026.06.017. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.